Sarah C Grünert, Terry G J Derks, Helen Mundy, R Neil Dalton, Jean Donadieu, Peter Hofbauer, Neil Jones, Sema Kalkan Uçar, Jamas LaFreniere, Enrique Landelino Contreras, Surekha Pendyal, Alessandro Rossi, Blair Schneider, Ronen Spiegel, Karolina M Stepien, Dorota Wesol-Kucharska, Maria Veiga-da-Cunha, Saskia B Wortmann
Glycogen storage disease type Ib (GSD Ib, biallelic variants in SLC37A4) is a rare disorder of glycogen metabolism complicated by neutropenia/neutrophil dysfunction. Since 2019, the SGLT2-inhibitor empagliflozin has provided a mechanism-based treatment option for the symptoms caused by neutropenia/neutrophil dysfunction (e.g. mucosal lesions, inflammatory bowel disease). Because of the rarity of GSD Ib, the published evidence on safety and efficacy of empagliflozin is still limited and does not allow to develop evidence-based guidelines...
January 17, 2024: Molecular Genetics and Metabolism